Clinical Trials
1,656 trialsBuMelMCRN001
University Health Network, Toronto
POM MM 014
Celgene
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Medical College of Wisconsin
COSMIC
ASH Research Collaborative
IFM2009-02
University Hospital, Lille
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
Otsuka Pharmaceutical Development & Commercialization, Inc.
KEYNOTE145
Acerta Pharma BV
UNIVERSAL
Allogene Therapeutics
MYELOCHOL
University Hospital, Bordeaux
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
University of Rochester
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Amgen
Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant
Ciusss de L'Est de l'Île de Montréal
iPREFER
The Christie NHS Foundation Trust
Natural Killer Cells and Bortezomib to Treat Cancer
National Institutes of Health Clinical Center (CC)
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Mayo Clinic
DREAMM 14
GlaxoSmithKline
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron Pharmaceuticals
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study
National Institutes of Health Clinical Center (CC)
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
University of Chicago
The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma
University of Alabama at Birmingham
DELICATESSE
Nantes University Hospital
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Bristol-Myers Squibb
FORTE
University of Turin, Italy
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
Hoffmann-La Roche
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
Flu-Mel-Vel
Hackensack Meridian Health
IFM-CRd
University Hospital, Toulouse
IFM2012-03
University Hospital, Lille
IFM2014-04
University Hospital, Lille
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Beth Israel Deaconess Medical Center
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
Ohio State University Comprehensive Cancer Center
RZD
Hackensack Meridian Health
Thal/Mel/Vel
Hackensack Meridian Health
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
Thomas Jefferson University
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma
Ciusss de L'Est de l'Île de Montréal
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Janssen Research & Development, LLC
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
EHCancer
Zagazig University
BMT
Massachusetts General Hospital
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Wake Forest University Health Sciences
KarMMa-2
Celgene
A Study of Ninlaro in Real World Clinical Practice in China
Takeda
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Biomarkers of AKI in Patients Receiving Daratumumab
Brigham and Women's Hospital